Literature DB >> 27486177

Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma.

Francesca Fontana1, Xia Ge2, Xinming Su1, Deep Hathi2, Jingyu Xiang1, Simone Cenci3, Roberto Civitelli4, Kooresh I Shoghi2, Walter J Akers2, Andre D'avignon5, Katherine N Weilbaecher6, Monica Shokeen7.   

Abstract

PURPOSE: We hypothesized that in multiple myeloma cells (MMC), high membrane biosynthesis will induce acetate uptake in vitro and in vivo Here, we studied acetate metabolism and targeting in MMC in vitro and tested the efficacy of 11C-acetate-positron emission tomography (PET) to detect and quantitatively image myeloma treatment response in vivo EXPERIMENTAL
DESIGN: Acetate fate tracking using 13C-edited-1H NMR (nuclear magnetic resonance) was performed to study in vitro acetate uptake and metabolism in MMC. Effects of pharmacological modulation of acetate transport or acetate incorporation into lipids on MMC cell survival and viability were assessed. Preclinical mouse MM models of subcutaneous and bone tumors were evaluated using 11C-acetate-PET/CT imaging and tissue biodistribution.
RESULTS: In vitro, NMR showed significant uptake of acetate by MMC and acetate incorporation into intracellular metabolites and membrane lipids. Inhibition of lipid synthesis and acetate transport was toxic to MMC, while sparing resident bone cells or normal B cells. In vivo, 11C-acetate uptake by PET imaging was significantly enhanced in subcutaneous and bone MMC tumors compared with unaffected bone or muscle tissue. Likewise, 11C-acetate uptake was significantly reduced in MM tumors after treatment.
CONCLUSIONS: Uptake of acetate from the extracellular environment was enhanced in MMC and was critical to cellular viability. 11C-Acetate-PET detected the presence of myeloma cells in vivo, including uptake in intramedullary bone disease. 11C-Acetate-PET also detected response to therapy in vivo Our data suggested that acetate metabolism and incorporation into lipids was crucial to MM cell biology and that 11C-acetate-PET is a promising imaging modality for MM. Clin Cancer Res; 23(2); 416-29. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27486177      PMCID: PMC5241171          DOI: 10.1158/1078-0432.CCR-15-2134

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  Fluxes and enzyme activities in central metabolism of myeloma cells grown in chemostat culture.

Authors:  N Vriezen; J P van Dijken
Journal:  Biotechnol Bioeng       Date:  1998-07-05       Impact factor: 4.530

2.  (11)C-acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment.

Authors:  Chieh Lin; Chi-Lai Ho; Shu-Hang Ng; Po-Nan Wang; Yenlin Huang; Yu-Chun Lin; Tzung-Chih Tang; Shu-Fan Tsai; Alain Rahmouni; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-16       Impact factor: 9.236

Review 3.  The gut microbiota, bacterial metabolites and colorectal cancer.

Authors:  Petra Louis; Georgina L Hold; Harry J Flint
Journal:  Nat Rev Microbiol       Date:  2014-09-08       Impact factor: 60.633

4.  1H NMR spectroscopic characterization of perchloric acid extracts from breast carcinomas and non-involved breast tissue.

Authors:  I S Gribbestad; S B Petersen; H E Fjøsne; S Kvinnsland; J Krane
Journal:  NMR Biomed       Date:  1994-06       Impact factor: 4.044

5.  11C-acetate PET/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET/CT.

Authors:  Chi-lai Ho; Sirong Chen; Yim Lung Leung; Thomas Cheng; Ka-nin Wong; Shing Kee Cheung; Raymond Liang; Chor Sang Chim
Journal:  J Nucl Med       Date:  2014-03-27       Impact factor: 10.057

Review 6.  A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease.

Authors:  J Paton-Hough; A D Chantry; M A Lawson
Journal:  Bone       Date:  2015-04-11       Impact factor: 4.398

7.  Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy.

Authors:  Samuel K McBrayer; Javelin C Cheng; Seema Singhal; Nancy L Krett; Steven T Rosen; Mala Shanmugam
Journal:  Blood       Date:  2012-03-27       Impact factor: 22.113

8.  Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.

Authors:  S L Dallas; I R Garrett; B O Oyajobi; M R Dallas; B F Boyce; F Bauss; J Radl; G R Mundy
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

9.  Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.

Authors:  Babatunde O Oyajobi; Giovanni Franchin; Paul J Williams; Donna Pulkrabek; Anjana Gupta; Steve Munoz; Barry Grubbs; Ming Zhao; Di Chen; Barbara Sherry; Gregory R Mundy
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

10.  Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts.

Authors:  Olaf Beckonert; Hector C Keun; Timothy M D Ebbels; Jacob Bundy; Elaine Holmes; John C Lindon; Jeremy K Nicholson
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

View more
  4 in total

Review 1.  Acetyl-CoA Synthetase 2 as a Therapeutic Target in Tumor Metabolism.

Authors:  Mengfang Liu; Na Liu; Jinlei Wang; Shengqiao Fu; Xu Wang; Deyu Chen
Journal:  Cancers (Basel)       Date:  2022-06-12       Impact factor: 6.575

2.  Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation.

Authors:  Antje Stolzenburg; Katharina Lückerath; Samuel Samnick; Martin Speer; Katharina Kneer; Jan-Stefan Schmid; Götz Ulrich Grigoleit; Susanne Hofmann; Ambros J Beer; Donald Bunjes; Stefan Knop; Andreas K Buck; Hermann Einsele; Constantin Lapa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-02       Impact factor: 9.236

3.  VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival.

Authors:  Francesca Fontana; Michael J Scott; John S Allen; Xiaoxia Yang; Grace Cui; Dipanjan Pan; Noriko Yanaba; Mark A Fiala; Julie O'Neal; Anne H Schmieder-Atteberry; Julie Ritchey; Michael Rettig; Kathleen Simons; Steven Fletcher; Ravi Vij; John F DiPersio; Gregory M Lanza
Journal:  Clin Cancer Res       Date:  2020-12-22       Impact factor: 13.801

4.  Targeting ACSS2 with a Transition-State Mimetic Inhibits Triple-Negative Breast Cancer Growth.

Authors:  Katelyn D Miller; Katherine Pniewski; Caroline E Perry; Sara B Papp; Joshua D Shaffer; Jesse N Velasco-Silva; Jessica C Casciano; Tomas M Aramburu; Yellamelli V V Srikanth; Joel Cassel; Emmanuel Skordalakes; Andrew V Kossenkov; Joseph M Salvino; Zachary T Schug
Journal:  Cancer Res       Date:  2021-01-07       Impact factor: 13.312

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.